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Objective To estimate the direct and indirect costs of
active smoking in Vietnam.
Method A prevalence-based disease-specific cost of
illness approach was utilised to calculate the costs
related to five smoking-related diseases: lung cancer,
cancers of the upper aerodigestive tract, chronic
obstructive pulmonary disease, ischaemic heart disease
and stroke. Data on healthcare came from an original
survey, hospital records and official government statistics.
Morbidity and mortality due to smoking combined with
the average per capita income were used to calculate
the indirect costs of smoking by applying the human
capital approach. The smoking-attributable fraction was
calculated using the adjusted relative risk values from
phase II of the American Cancer Society Cancer
Prevention Study (CPS-II). Costs were classified as
personal, governmental and health insurance costs.
Results The total economic cost of smoking in 2011
was estimated at 24 679.9 billion Vietnamese dong
(VND), equivalent to US$1173.2 million or approximately
0.97% of the 2011 gross domestic product. The direct
costs of inpatient and outpatient care reached 9896.2
billion VND (US$470.4 million) and 2567.2 billion VND
(US$122.0 million), respectively. The government’s
contribution to these costs was 4534.3 billion VND (US
$215.5 million), which was equivalent to 5.76% of its
2011 healthcare budget. The indirect costs (productivity
loss) due to morbidity and mortality were 2652.9 billion
VND (US$126.1 million) and 9563.5 billion VND (US
$454.6 million), respectively. These indirect costs
represent about 49.5% of the total costs of smoking.
Conclusions Tobacco consumption has large negative
consequences on the Vietnamese economy.
BACKGROUND
In addition to damaging health, tobacco use
imposes costs on individuals, their families and
society as a whole. The estimates of these costs
highlight the economic burden associated with
tobacco use and help justify government interven-
tion in the tobacco market.
There are only a few estimates of these costs in
Asia, where the majority of the world’s smokers
live. Our literature review examined the estimates
for the cost of smoking in Singapore,1 Korea,2
Myanmar,3 Taiwan,4 Bangladesh,5 China,6 Hong
Kong,7 India,8 and Vietnam.9 10 All of these studies
used a prevalence-based approach, and eight out of
nine employed a societal perspective. However, not
all studies included indirect costs (IC), and only
four estimated direct non-medical costs, such as
transportation to and from medical facilities.
The two studies in Vietnam suffered from many
limitations. Ross et al10 measured the social cost of
hospitalisation related to three major tobacco-
related diseases: lung cancer, chronic obstructive
pulmonary disease (COPD) and ischaemic heart
diseases. It was the first study to measure the eco-
nomic burden of smoking in Vietnam and esti-
mated that the cost was at least 1602 billion
Vietnamese dong (VND; equivalent to US$76
million in 2005. However, this study covered a
limited number of diagnoses, only considered costs
due to hospitalisation and did not include costs
associated with premature death. In addition, they
only assessed 390 patients. The second study con-
ducted in Vietnam updated the 2007 findings of
Ross et al10 using 2010 data9 and addressed some
limitations of the previous effort by adding out-
patient healthcare and self-treatment costs. The
total tobacco-related costs were estimated at 2300
billion VND (US$109 million), not including IC.
This study was designed to overcome the limita-
tions of the two previous investigations by calculat-
ing both the direct and indirect health costs of five
smoking-related diseases that are responsible for
almost 75% of all smoking-related deaths in
Vietnam. IC in our study include lost productivity
and revenue due to premature smoking-related
deaths. In addition, we used original survey data
based on a large sample of patients treated in 13
hospitals representing all levels of the health service
system to estimate the unit cost of inpatient and out-
patient treatment of a smoking-related disease
episode. We did not include self-treatment costs due
to the uncertainty of the patients’ self-diagnoses and
the significant number of non-responses regarding
self-treatment on our questionnaire. There are no
statistics on self-treatment expenses by disease cat-
egory in Vietnam.
The goal of this study was to inform researchers,
policymakers and the public of the negative eco-
nomic impact of tobacco use in Vietnam. It is
intended to motivate policymakers to adopt appro-
priate policy reforms to reduce costs associated
with tobacco use in Vietnam. In addition, our
research contributes to the understanding of the
economic burden of tobacco use in developing
countries. The methodology used in this investiga-
tion can be applied to other studies in developing
countries in which both resources and valid data
are scarce. The large range of costs estimated using
different relative risks (RRs) also demonstrates how
the estimate can vary with different assumptions
and highlights the need for country-specific esti-
mates of RR.
DATA AND METHODS
Understanding the healthcare system is crucial for
calculating the actual cost of smoking in Vietnam.
Healthcare is delivered at four levels: central, pro-
vincial, district and community. The district and
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community levels only provide primary healthcare, whereas spe-
cialised healthcare is available at the central and provincial
levels. The cost of healthcare is covered either by private parties
or by the government.
There are two health insurance schemes: public and private.
Public health insurance is compulsory for all employees, and the
costs are shared by the employer (two-thirds) and employee
(one-third). Private health insurance supplements public health
insurance; it is profit driven and primarily used by wealthier
individuals.
The patients and insurance companies share the operational
costs for inpatient and outpatient care (eg, medical exams,
drugs, lab tests), with the insurance covering 80% and the
remaining 20% being covered by patients ‘out of pocket’. The
overhead costs including labour costs and asset depreciation are
covered by the government. We utilised a prevalence-based,
disease-specific approach to estimate the economic costs of the
five most common diagnoses related to smoking: lung cancer,
cancers of the upper aerodigestive tract, COPD, ischaemic heart
disease and stroke. According to the WHO, these diseases are
responsible for more than 75% of all smoking-attributable
deaths in Vietnam.11
The costs of smoking include both direct costs (DC) and IC.
DC consist of medical costs (service fees, overhead costs, drugs
not included in the service fees) and non-medical costs (trans-
portation, supplemental foods). IC include patients’ income
losses due to sick leave and premature death, as well as income
losses for family members providing patient care.
DC were estimated by employing methodology recommended
by the WHO.12 The smoking-attributable DC of a given disease
(SDCijk) are the product of a smoking-attributable fraction
(SAFij) and the total medical and non-medical DC of this
disease (DCik):
SDCijk ¼ SAFij DCik
where (i) represents the five diseases, ( j) is sex, and (k) indicates
the type of healthcare service (inpatient or outpatient).
The annual DC were estimated as:
DCijk ¼ nijk Qik
where nijk is the annual number of episodes and Qik is the
average direct cost for treating a typical episode (one hospitalisa-
tion or one outpatient visit).
We conducted a hospital-based cost study to estimate Qik. A
convenience sample of 13 public hospitals was selected based
on the level of healthcare service provided and the geographical
areas so that they represent both north and south Vietnam. Six
were national hospitals, five were provincial hospitals and two
represented district-level hospitals. All patients aged 18+ years
discharged from these hospitals between March and October
2011 who were diagnosed with any of the five diseases of inter-
est were invited to participate. The goal was to collect informa-
tion from at least 600 patients with each diagnosis. In the end,
the study enrolled 3128 inpatients (74.4% male, 25.6% female)
with an average age of 63; 727 had lung cancer, 679 had cancer
of the upper aerodigestive tract, 627 had COPD, 675 had
ischaemic heart disease and 420 had stroke. The average
number of hospital days was 38.1. About 86% of these patients
had health insurance. The majority (64%) were treated in
national hospitals, 23% were treated in provincial hospitals and
3% of the patients’ data came from district hospitals. In addition
to data from hospital discharge records, trained hospital staff
interviewed the patients on the day of discharge using a Patient
Exit Questionnaire that collected information on patients’ socio-
demographic characteristics, smoking status, number of days off
due to illness (both due to hospitalisation and outpatient visits),
number of days spent by relatives providing care, transportation
expenditures, meals, drug/medical supplies purchased outside
the hospital, informal service fees, number of outpatient visits
during the previous 3 months related to the discharge diagnoses
and expenditures for each of these visits.
Qik was calculated by summing the average direct user’s cost
(covered by patients and insurance companies), the average
direct provider’s cost (covered by the government) and the
average direct non-medical user’s cost per unit of treatment.
The direct user’s costs included service fees paid to healthcare
facilities, informal fees and the cost of drugs purchased outside
the hospital. The sum of these expenditures for all survey parti-
cipants was divided by the total number of disease-specific hos-
pitalisations or the number of outpatient visits to estimate the
average user’s direct cost for one episode of hospitalisation or
one outpatient visit.
The average provider’s costs were estimated using data from
annual hospital reports. These costs included overhead costs,
labour costs not covered by service fees, and asset depreciation.
Hospital departments were classified as those directly (eg, labs)
and indirectly (eg, finance) involved in patient treatment. The
total costs incurred by each department not covered by service
fees were extracted from annual hospital reports.13 The labour
and depreciation costs of directly involved departments plus a
share of the overhead costs from the indirectly involved depart-
ments were divided by the total units of treatment (inpatient
days and outpatient visits) to generate an average provider cost.
The allocation of overhead costs was based on the number of
annual inpatient days and outpatient visits, and the relative costs
of these two types of healthcare services. The cost for one
inpatient day was multiplied by the average number of days
spent in the hospital for each diagnosis to obtain the average
provider’s cost per hospitalisation. The average direct non-
medical cost included transportation to and from the hospital
for the patient and their family members and the cost of food
while being hospitalised. These data came from the patient’s
questionnaire.
The annual number of hospital admissions and the number of
outpatient visits came from the Health Statistics Yearbook
2011.14
SAFij was estimated using the following formula:
SAFij ¼ P ðRRij  1ÞP ðRRij  1Þ þ 1 100%
where RR is the RR for cause-specific mortality related to
tobacco use, P is the prevalence of ever smokers, and i and j are
defined as above. P is based on the 2010 Global Adult Tobacco
Survey in Vietnam that estimates that 66.5% of males and 2.5%
of females are ever smokers.
Since Vietnam does not have an estimate of cause-specific
morbidity RR, we used the cause-specific mortality RRs based
on phase II of the American Cancer Society Cancer Prevention
Study (CPS-II) adjusted for important covariates such as age;
race; education; marital status; ‘blue collar’ occupation; weekly
vegetable and citrus fruit consumption; vitamin, alcohol, and
aspirin use; body mass index; exercise; dietary fat consumption;
and family history of cancer, hypertension and diabetes.15–17
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This adjusted RR from CPS-II has been employed by the major-
ity of studies in Vietnam.18 The estimates of alternative RRs
from China19 and Taiwan,4 which are substantially lower com-
pared to CPS-II, have been recently opened to doubt due to
new research results demonstrating much larger risks associated
with smoking.20
Smoking-attributable IC (productivity losses) include costs
related to morbidity and mortality. The IC of morbidity (ICMB)
were estimated using the following formula:
ICMBij ¼ SAFij DLijk  S
where DLijk is the annual number of working days lost due to
hospitalisations and outpatient visits by patients and their care-
givers, S is the average daily income obtained from VLSS
2010,21 and SAFij is defined as above. We assume that the
number of working days lost due to hospitalisations equals
the number of inpatient days adjusted for a 6-day work week.
The number of working days lost due to one episode of out-
patient care was obtained from patients’ questionnaires.
The IC of mortality (ICMT) for each disease category by sex
and 5-year age group starting at the age of 35 were estimated as:
ICMTija ¼ SAFij Nija  PVLEja
where PVLEja is the present value of lifetime earnings for sex ( j)
and age group (a), Nija is the number of deaths by disease (i) by
sex ( j) and age group (a), and SAFij is defined as above except for
males for whom we replace P with the smoking impact ratio
(SIR) because the prevalence of smoking is a poor proxy for the
cumulative hazards of smoking among males.22 SIR was calcu-
lated using the lung cancer mortality rates among the whole
Vietnamese population, (non-smokers and smokers) and the ref-
erence population (CPS-II).23 For females, SIR was approximated
by P due to their traditionally low smoking prevalence. Nija was
taken from a 2008 study on the burden of disease and injury for
Vietnam.24 These mortality estimates were based on a national
representative cause of death survey in 192 communities located
in 16 provinces using verbal autopsy methods.
PLVEja was estimated separately for males and females using a
human capital approach as described by Max et al.25 26 We
assumed that the 2011 labour force (defined as the population
over 15 years of age) was the same as that for 2010, which
means that 80% of males and 71% of females were potentially
active in the labour force,27 and that the annual productivity
growth rate was 6%, which approximates the average real
growth rate of gross domestic product (GDP) in Vietnam
between 2008 and 2010. A discount rate of 3% was employed
to convert a stream of earnings into its current worth.
RESULTS
Table 1 shows the average direct medical and non-medical costs
per one episode of hospitalisation and one outpatient visit by
diagnosis. The costs are lowest for COPD and are highest for
cancers.
Table 2 presents the estimated number of hospitalisations
(hospital admissions) and the number of outpatient visits in
2011 for the entire country, as well as the SAFs for males and
females.
Table 3 shows that the total smoking-attributable DC of
inpatient and outpatient care are 9896.2 billion VND (US
$470.4 million) and 2567.2 billion VND (US$122.0 million),
respectively. The total DC reached 12 463.5 billion VND (US
$592.5 million), with COPD being the most expensive. About
36.4% of these costs (4534.3 billion VND or US$215.5
million) were covered by the government while the rest were
covered by private expenditures (by patients and insurance
companies).
The smoking-attributable IC (productivity loss) due to mor-
bidity and mortality based on the RR from CPS-II are presented
in table 4. The total morbidity costs were primarily driven by
inpatient care, which resulted in 2429.5 billion VND (US$115.5
million) productivity loss, while the outpatient care caused
223.4 billion VND (US$10.6 million) of productivity loss.
Tobacco use caused about 37 614 male and 12 269 female
deaths in Vietnam in 2010, which represents 13% and 5% of all
male and female deaths, respectively. Assuming that the number
of deaths in 2011 was similar to the number of deaths in 2010,
the total smoking-attributable mortality costs reached 9563.5
billion VND (US$454.6 million), accounting for approximately
78.3% of the total IC of smoking.
The total economic cost of smoking for five smoking-related
diseases was 24 679.9 billion VND (US$1173.2 million), with
lung cancer being the most expensive (table 5). This represents
approximately 0.97% of Vietnam’s 2011 GDP.14
DISCUSSION
We found that the total costs of smoking in Vietnam amounted
to 24 679.9 billion VND (US$1173.2million) or 0.97% of
Vietnam’s 2011 GDP. The share of GDP lost due to smoking is







Male Female Male Female Male Female
Lung cancer 93.1 22.3 34 875 12 253 101 136 35 534
Upper aerodigestive
tract cancers
82.5 11.1 27 752 9751 80 482 28 277
COPD 86.7 22.0 424 880 149 282 1 232 151 432 918
Ischaemic heart
disease
37.4 2.7 6578 2311 19 076 6702
Stroke 31.8 2.9 84 218 29 590 244 232 85 811
COPD, chronic obstructive pulmonary disease; SAF, smoking-attributable fraction.
Table 1 Average direct medical and non-medical costs by
healthcare service type
Diagnosis
Mean total healthcare cost
per hospitalisation (SD) in
thousand VND and in US$
Mean of total healthcare
cost per outpatient visit
(SD) in thousand VND
and in US$

























COPD, chronic obstructive pulmonary disease; VND, Vietnamese dong.
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comparable to those reported for China28 (0.7%) and Korea2
(ranging from 0.59% to 0.78%), but higher compared to that
reported for Taiwan4 (0.4%). None of these studies included
the direct non-medical costs associated with smoking. Our esti-
mate of total smoking-associated costs is substantially larger
than both the 2005 study10 (1602 billion VND or US$76
million) and 2010 study (2300 billion VND or US$109 million)
conducted in Vietnam. This is because we took a more compre-
hensive approach that assessed more smoking-related diseases
and calculating associated IC.
The IC of smoking represent about 49.5% of the total costs.
This is comparable to the ratio of direct and IC in the USA,23
slightly higher than in Hong Kong7 (40%), but lower compared
to Taiwan (77%). The ratio of DC and IC is highly sensitive to
healthcare prices and labour costs.
The government covered approximately 36.4% of
smoking-related medical costs (4534.3 billion VND or US
$215.5 million), and that amount represented about 5.76% of
its 2011 healthcare budget. The government’s share of expendi-
tures was larger than the 2005 estimate of 19%. The reason for
this discrepancy may be due to methodological differences, but
there is also a possibility that the government share of costs is
increasing over time. The present study has several limitations.
First, owing to data collection complexity and feasibility, we
could not assess the costs associated with all tobacco-related dis-
eases. However, the five included diseases are responsible for
over 75% of all smoking-attributable mortality in Vietnam
(author’s estimation based on data from29). Second, our study
did not estimate the cost of exposure to secondhand smoke or
self-treatment costs. Owing to these limitations, we most likely
underestimated the total cost of smoking. Third, although con-
venience sampling was used to select the hospitals, we aimed to
include facilities that typically treat all the diseases covered in
our study and represent the major geographical areas of
Vietnam. Fourth, we used the average income in Vietnam to
estimate the IC of smoking. Since smokers are primarily males,
Table 3 Smoking-attributable direct costs*
Studied smoking-related
disease







Lung cancer 978.3 1.394.1 162.6 565.1 3101.1
(US$46.5) (US$66.3) (US$7.7) (US$26.9) (US$147.4)
Upper aerodigestive tract cancers 1122.6 904.1 163.3 128.8 2318.8
(US$53.4) (US$43.0) (US$7.8) (US$6.1) (US$110.2)
COPD 1736.7 3266.7 259.8 1163.3 6426.4
(US$82.6) (US$155.3) (US$12.3) (US$55.3) (US$305.5)
Ischaemic heart disease 6.2 86.4 1.5 11.9 105.9
(US$0.3) (US$4.1) (US$0.1) (US$0.6) (US$5.0)
Stroke 96.1 305.2 7.2 103.6 512.1
(US$4.6) (US$14.5) (US$0.3) (US$4.9) (US$24.3)
Total costs 3939.8 5956.4 594.5 1972.8 12 463.5
(US$187.3) (US$283.2) (US$28.3) (US$93.8) (US$592.5)
*Values are in VND billions and US$ millions.COPD, chronic obstructive pulmonary disease; VND, Vietnamese dong.
Table 4 Smoking-attributable indirect costs
Studied smoking-related disease Morbidity cost Mortality cost Total indirect cost
Lung cancer 2309.2 (US$109.8) 3226.4 (US$153.4) 5535.6 (US$263.1)
Upper aerodigestive tract cancers 220.7 (US$10.5) 979.2 (US$46.5) 1199.9 (US$57.0)
COPD 55.3 (US$2.6) 1636.7 (US$77.8) 1692.0 (US$80.4)
Ischaemic heart disease 3.4 (US$0.2) 918.7 (US$43.7) 922.1 (US$43.8)
Stroke 64.3 (3.1) 2802.4 (US$133.2) 2866.7 (US$136.3)
Total costs 2652.9 (US$126.1) 9563.5 (US$454.6) 12 216.4 (US$580.7)
*Values are in VND billions and US$ millions.
COPD, chronic obstructive pulmonary disease; VND, Vietnamese dong.




Lung cancer VND 8635.8
US$ 410.5








Total costs VND 24 679.9
US$ 1173.2
Total 2011 costs % GDP 0.97%
*Values are in VND billions and US$ millions.
COPD, chronic obstructive pulmonary disease; GDP, gross domestic product; VND,
Vietnamese dong.
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who have higher incomes compared to females, we most likely
underestimated this cost. Fifth, we only accounted for sick days
spent in hospitals for current episodes and related outpatient
episodes. This most likely underestimated the number of days a
patient was not working because many Vietnamese rely on self-
treatment and take time off work even before seeking medical
care. Finally, we did not capture self-treatment costs. Despite
these limitations, our findings demonstrate that the annual cost
of smoking in Vietnam (24 679.9 billion VND) is substantially
higher than the contribution of the tobacco industry to the
annual budget (15 000–17 000 billion VND in taxes). The
results of this study provide evidence of the large negative eco-
nomic consequences of tobacco use on the Vietnamese
economy.
What this paper adds
▸ The existing estimates of the costs associated with smoking
in Vietnam indicate that the society suffered an economic
loss due to tobacco use.
▸ The two existing estimates of the costs of smoking in
Vietnam suffer from major limitations that result in
underestimation of the total costs. Until this study, Vietnam
did not have an estimate of the indirect costs of smoking.
▸ This study provides a more comprehensive and refined
estimate of the total costs of smoking in Vietnam including
the indirect costs using original survey data. Our research
also improves our understanding of the economic burden of
tobacco use in developing countries while demonstrating the
feasibility of conducting such studies in countries where
resources and valid data are scarce.
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